-
581
-
582
-
583
-
584
-
585
Statins resulted in smaller neuronal soma size.
Published 2025“…Statin treatment decreased cell sizes in the larger cells more than in the smaller cells as seen in the greater divergence between lines plotted for larger cell somas (bottom panel). …”
-
586
-
587
-
588
Study Data.
Published 2025“…It has also been hypothesized that the bradycardia and rare instances of cardiac arrest occurring after the use of sugammadex may be due to a transient decrease in circulating corticosteroids, causing a temporary ‘mini Addisonian crisis.’ …”
-
589
Study outcomes.
Published 2025“…It has also been hypothesized that the bradycardia and rare instances of cardiac arrest occurring after the use of sugammadex may be due to a transient decrease in circulating corticosteroids, causing a temporary ‘mini Addisonian crisis.’ …”
-
590
Patient characteristics.
Published 2025“…It has also been hypothesized that the bradycardia and rare instances of cardiac arrest occurring after the use of sugammadex may be due to a transient decrease in circulating corticosteroids, causing a temporary ‘mini Addisonian crisis.’ …”
-
591
-
592
Univariate and multivariate analysis of variables associated with good and poor responders to TFESI.
Published 2025Subjects: -
593
-
594
The serum concentrations of cytokines between good responders and poor responders to TFESI.
Published 2025Subjects: -
595
Demographic data and baseline characteristics between good and poor responders to TFESI.
Published 2025Subjects: -
596
-
597
-
598
<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate....
Published 2025“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”
-
599
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; <sup>$</sup>(P < 0.05) significant vs. …”
-
600